by Canadian Medical Association Journal A colorized scanning electron micrograph of the SARS-CoV-2 virus. Credit: NIAID The antiviral drugs molnupiravir and nirmatrelvir–ritonavir (Paxlovid), when used to treat nonsevere COVID-19, most likely reduce the risk of subsequent progression to hospitalization and death, according to new research published in CMAJ (Canadian Medical Association Journal). As most trials have focused...
